Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunovaccine has reported that Pfizer Animal Health is expected to exercise a licensing option on its vaccine enhancement and delivery platform to develop a third livestock vaccine.
Subscribe to our email newsletter
It represents an important milestone for Immunovaccine as it further validates the potential of its vaccine platform, and enables the company to apply the upfront signing fees, and any milestone and royalty payments to further advance its vaccine pipeline.
Immunovaccine’s patented vaccine enhancement platform uses liposomes in an oil depot to present antigens and adjuvants to the immune system. In preclinical models, the platform creates a depot effect that prolongs the immune system’s exposure to the vaccine, resulting in a rapid, potent, and long lasting immune response after a single dose.
Randal Chase, president and CEO of Immunovaccine, said: “We are pleased that Pfizer Animal Health will now be integrating our technology into a third vaccine product.”
Immunovaccine is a clinical stage vaccine development company focused on the commercialization of its novel vaccine technology and product candidates. Immunovaccine continues to strengthen its vaccine pipeline through licensing and strategic partnering to develop therapeutic cancer and infection disease vaccines.